PRRT Resources
EDUCATIONAL WEBINARS
"Understanding Alpha & The Evolving PRRT Landscape"
Sep 22, 2025
​
The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment.
"PRRT Nurse's Perspective: What to Expect With PRRT"
March 7, 2025
​
Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety.
LACNETS Educational Event
January 11, 2024
Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials.
Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023.
Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, Dr. Amir Iravani, shares the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry.
NET expert and radiologist Dr. Thomas Hope of UCSF addresses the latest in NET imaging and PRRT.
Nuclear Medicine Physician Dr. Erik Mittra provides an update on PRRT. Plus, hear from a NET patient who has received multiple rounds of PRRT treatments.
Nuclear medicine specialist Dr. Delpassand provides an update on the exciting advances in NET Management including Cu64 DOTATATE & Alpha PRRT.
READ
-
-
This review looks at the factors that influence patients’ decisions about radioligand therapy, how they feel about when it should be used in their care, the challenges they may face in accessing this treatment, and the disparities—such as those related to race or geography—that can affect access to high-quality care.​
-
-
New Article: Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients
-
This is an excellent review article giving a thorough overview of the evidence behind somatostatin receptor targeted therapies, which includes long-acting somatostatin analogues (SSAs) octreotide LAR and lanreotide, and radiolabeled SSAs, otherwise known as PRRT. The article offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing.​
-
PRRT PATIENT/CAREGIVER STORIES
PRRT Patient/Caregiver Stories
PODCAST
%20(1).png)
%20(2).png)
%20(1).png)
.png)
READING MATERIALS
NANETS NET GUIDELINES BY TOPIC
This is for informational use only. Neuroendocrine Cancer Foundation is not endorsing or recommending any particular treatment or trials. Neuroendocrine Cancer Foundation encourages you to discuss your individual needs and options with your medical team. For more information about available clinical trials, go to www.clinicaltrials.gov.